Literature DB >> 30097789

The effects of septal myectomy and alcohol septal ablation for hypertrophic cardiomyopathy on the cardiac conduction system.

Patrick Fitzgerald1,2, Fred Kusumoto3,4.   

Abstract

AV conduction abnormalities are observed in 15-30% of patients with hypertrophic cardiomyopathy but are usually not severe enough to require permanent pacemaker implant. Both septal myectomy and alcohol septal ablation are effective options to relieve symptoms due to left ventricular outflow tract gradient in patients with hypertrophic cardiomyopathy but have procedure-specific effects on AV conduction and the His Purkinje system. Septal myectomy is associated with the development of LBBB in 50-100% of patients, while alcohol septal ablation is associated with RBBB in 37-70% of patients. Baseline abnormalities in the contralateral bundles and the presence of conduction disease have an important impact on the likelihood of the development of AV block for both of these therapies. AV block requiring permanent pacing occurs in approximately 2-3% of patients after septal myectomy and 10-15% of patients after alcohol septal ablation. Permanent pacemaker implant after alcohol septal ablation is more common in older patients (> 55 years old 13 vs. < 55 years old 5%; p = 0.06). Improved outcomes for septal myectomy and alcohol septal ablation are observed in experienced centers. Septal reduction therapies should be performed at medical centers with a dedicated hypertrophic cardiomyopathy program using a multidisciplinary approach.

Entities:  

Keywords:  Alcohol septal ablation; Bundle branch block; Hypertrophic cardiomyopathy; Pacemaker; Septal myectomy

Mesh:

Substances:

Year:  2018        PMID: 30097789     DOI: 10.1007/s10840-018-0433-0

Source DB:  PubMed          Journal:  J Interv Card Electrophysiol        ISSN: 1383-875X            Impact factor:   1.900


  43 in total

1.  Surgical relief of diffuse subvalvular aortic stenosis.

Authors:  J W KIRKLIN; F H ELLIS
Journal:  Circulation       Date:  1961-10       Impact factor: 29.690

2.  Asymmetrical hypertrophy of the heart in young adults.

Authors:  D TEARE
Journal:  Br Heart J       Date:  1958-01

3.  Updated meta-analysis of septal alcohol ablation versus myectomy for hypertrophic cardiomyopathy.

Authors:  Shikhar Agarwal; E Murat Tuzcu; Milind Y Desai; Nicholas Smedira; Harry M Lever; Bruce W Lytle; Samir R Kapadia
Journal:  J Am Coll Cardiol       Date:  2010-02-23       Impact factor: 24.094

4.  Controversies in cardiovascular medicine. Hypertrophic obstructive cardiomyopathy: alcohol septal ablation.

Authors:  Michael A Fifer; Ulrich Sigwart
Journal:  Eur Heart J       Date:  2011-03-29       Impact factor: 29.983

5.  Severe cardiac conduction disturbances and pacemaker implantation in patients with hypertrophic cardiomyopathy.

Authors:  Roberto Barriales-Villa; Raúl Centurión-Inda; Xusto Fernández-Fernández; Martín F Ortiz; Luisa Pérez-Alvarez; Isabel Rodríguez García; Manuel Hermida-Prieto; Lorenzo Monserrat
Journal:  Rev Esp Cardiol       Date:  2010-08       Impact factor: 4.753

6.  Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy.

Authors:  Uma S Valeti; Rick A Nishimura; David R Holmes; Philip A Araoz; James F Glockner; Jerome F Breen; Steve R Ommen; Bernard J Gersh; A Jamil Tajik; Charanjit S Rihal; Hartzell V Schaff; Barry J Maron
Journal:  J Am Coll Cardiol       Date:  2007-01-04       Impact factor: 24.094

7.  Radiofrequency septal reduction in symptomatic hypertrophic obstructive cardiomyopathy.

Authors:  Karl Crossen; Marsha Jones; Christopher Erikson
Journal:  Heart Rhythm       Date:  2016-04-27       Impact factor: 6.343

8.  Familial conduction system disease associated with hypertrophic cardiomyopathy.

Authors:  Ajay Bahl; Uma Nahar Saikia; Kewal K Talwar
Journal:  Int J Cardiol       Date:  2007-04-18       Impact factor: 4.164

9.  Safety and efficacy of coil embolization of the septal perforator for septal ablation in patients with hypertrophic obstructive cardiomyopathy.

Authors:  Israel Guerrero; Abhijeet Dhoble; Mark Fasulo; Ali E Denktas; Shehzad Sami; Sangbum Choi; Prakash Balan; Salman A Arain; Richard W Smalling
Journal:  Catheter Cardiovasc Interv       Date:  2016-08-11       Impact factor: 2.692

10.  Contrast-enhanced computed tomography with myocardial three-dimensional printing can guide treatment in symptomatic hypertrophic obstructive cardiomyopathy.

Authors:  Yasuhiro Hamatani; Makoto Amaki; Hideaki Kanzaki; Kizuku Yamashita; Yasuteru Nakashima; Atsushi Shibata; Atsushi Okada; Hiroyuki Takahama; Takuya Hasegawa; Yusuke Shimahara; Yasuo Sugano; Tomoyuki Fujita; Isao Shiraishi; Satoshi Yasuda; Junjiro Kobayashi; Toshihisa Anzai
Journal:  ESC Heart Fail       Date:  2017-07-04
View more
  4 in total

Review 1.  Contemporary Therapies and Future Directions in the Management of Hypertrophic Cardiomyopathy.

Authors:  Elizabeth Packard; Alejandro de Feria; Supriya Peshin; Nosheen Reza; Anjali Tiku Owens
Journal:  Cardiol Ther       Date:  2022-10-15

2.  Percutaneous Intramyocardial Septal Radiofrequency Ablation in Patients With Drug-Refractory Hypertrophic Obstructive Cardiomyopathy.

Authors:  Mengyao Zhou; Shengjun Ta; Rebecca T Hahn; David H Hsi; Martin B Leon; Rui Hu; Jun Zhang; Lei Zuo; Jing Li; Jing Wang; Bo Wang; Xiaoli Zhu; Jiani Liu; Yupeng Han; Xiaojuan Li; Bo Xu; Lei Zhang; Lihong Hou; Chao Han; Jincheng Liu; Liwen Liu
Journal:  JAMA Cardiol       Date:  2022-05-01       Impact factor: 30.154

3.  Surgical septal myectomy outcome for obstructive hypertrophic cardiomyopathy after alcohol septal ablation.

Authors:  Qiulan Yang; Changsheng Zhu; Hao Cui; Bing Tang; Shengwei Wang; Qinjun Yu; Shihua Zhao; Yunhu Song; Shuiyun Wang
Journal:  J Thorac Dis       Date:  2021-02       Impact factor: 2.895

Review 4.  Alcohol Septal Ablation: An Option on the Rise in Hypertrophic Obstructive Cardiomyopathy.

Authors:  Victor Arévalos; Juan José Rodríguez-Arias; Salvatore Brugaletta; Antonio Micari; Francesco Costa; Xavier Freixa; Mónica Masotti; Manel Sabaté; Ander Regueiro
Journal:  J Clin Med       Date:  2021-05-24       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.